Helicobacter%20pylori%20infection News

News

Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication

20230803130000

In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.

Vonoprazan-amoxicillin combo on par with B-quadruple therapy for H. pylori infection

20230423120000

Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.

Alcohol intake tied to lower H. pylori infection risk, with caveat

20230222110000

A recent meta-analysis has revealed a decreased risk of Helicobacter pylori infection among alcohol drinkers as compared with nondrinkers, with wine and mixed types of alcohol showing greater infection reduction than beer.

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases

Tristan Manalac, 20221021090000

Vonoprazan, a potassium competitive acid blocker (PCAB), is better than proton pump inhibitors (PPI) for the treatment of Helicobacter pylori and erosive oesophagitis, according to a new meta-analysis.

Gastric disease prevalence peaks during middle age, late adulthood

Tristan Manalac, 20220810090000

There appears to be a twin-peak prevalence profile (TPP) for diseases of the stomach, including Helicobacter pylori (Hp) infection, gastric cancer (GC), gastric intraepithelial neoplasia (GIN), and gastritis, according to a recent China study. The first peak typically occurs during middle-adulthood while the second peak happens in late life.

H. pylori eradication: Triple therapy with 1-week vonoprazan as good as with 2-week PPI

20220624060000

One-week vonoprazan-based triple therapy is well tolerated and has comparable efficacy as the 2-week proton pump inhibitor (PPI)-based triple therapy for first-line Helicobacter pylori eradication, according to a study.

Vonoprazan trumps PPI in ridding off H. pylori

Pearl Toh, 20211118140100

Vonoprazan-containing triple- or dual-therapy regimens are superior to lansoprazole triple therapy in eradicating Helicobacter pylori (H. pylori), according to the phase III pHalcon-HP study presented at ACG 2021.

Vonoprazan-based triple therapy knocks out resistant H. pylori infection

Jairia Dela Cruz, 20201120140000

Vonoprazan-based triple therapy demonstrates potent activity and is well tolerated in the first-line treatment of patients with Helicobacter pylori, leading to high eradication of infection, including strains resistant to clarithromycin, as shown in a study from Japan.

Cranberry juice may help curb H pylori infection

Cranberry juice a potential treatment for H pylori infection?

Pearl Toh, 20200919143500

Consuming cranberry juice twice daily for 8 weeks can help suppress Helicobacter (H.) pylori infection among Chinese adults, suggests a randomized study — thus opening the door to using cranberry juice as a complementary approach to H. pylori management.

Mass eradication of H. pylori infection eliminates gastric cancer threat

20200902140000

Population-based eradication of Helicobacter pylori infection leads to a marked reduction in gastric cancer incidence with no increase in the likelihood of adverse consequences, a study has found.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules